- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03209505
The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)
August 27, 2021 updated by: Eric R. Ritchey, University of Houston
This study examines the development of Lid Wiper Epitheliopathy (LWE) in individuals fit with contact lenses having difference coefficients of friction (CoF)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary study objectives are to determine the amount of Lid Wiper Epitheliopathy (LWE) induced in subjects after contact lens fitting that do not have LWE at study enrollment.
Subjects in the trial will be fit in 2 contact lenses with different coefficients of friction (CoF).
One eye will be fit in a contact lens with a low coefficient of friction (Acuvue Oasys®, Johnson & Johnson Vision, Jacksonville FL) while the contralateral eye will be fit in a contact lens with a high CoF (Air Optix® Night & Day® Aqua, Ft.
Worth, TX), as reported in the scientific literature.
The eye receiving each lens will be assigned randomly.
The presence of LWE will be assessed at 2 different time points, approximately 2 hours after contact lens fitting and approximately after 7 days of contact lens wear.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77204
- The Ocular Surface Institute, The University of Houston College of Optometry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 46 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be able to read and understand the study informed consent
- Must be a minimum of 18 years of age and less than 46 years of age at study enrollment
- Must be healthy non-soft contact lens wearers (neophytes), or experienced contact lens wearers that have not worn their contact lenses for a minimum of 7 days
- Have a spherical equivalent refractive error between -0.75 to -6.50DS at the spectacle plane
- The subject must be able to attend study visits at the prescribed visit times and adhere to the study instructions
Exclusion Criteria:
- Pregnant and/or lactating females by self-report
- Presence of current LWE on the upper eyelid (>0.5 in height or width)
- Has greater than -1.00DC of refractive cylinder
- Has greater than 1.00D of anisometropia
- Is aphakic
- Has clinically significant corneal or conjunctival staining that would prevent contact lens fitting, as assessed with sodium fluorescein dye
- Has significant ocular surface disease (e.g. Sjögrens Disease, Stevens-Johnson Syndrome, etc.) or significant Dry Eye Syndrome
- Has clinically significant corneal vascularization or central corneal scaring
- Has active ocular surface infection (e.g. conjunctivitis)
- Has a positive history of eyelid surgery or trauma
- Has a positive history of refractive surgery
- Takes medications that significantly impact contact lens comfort and/or ocular surface health
- Has taken part in another contact lens or contact lens solution clinical trial within the last 7 days
- Is unwilling to have eyes photographed or video recorded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Eye 1: Low coefficient of friction
Subjects will be fit in a different contact lens brand in each eye.
Assignment of the contact lens to each eye will be randomized.
Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
|
FDA approved contact lens, fit for daily wear
|
|
Other: Eye 2: High coefficient of friction
Subjects will be fit in a different contact lens brand in each eye.
Assignment of the contact lens to each eye will be randomized.
Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
|
FDA approved contact lens, fit for daily wear
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lid Wiper Epitheliopathy
Time Frame: One week post contact lens fitting
|
Lid Wiper Staining of the Upper Eyelid.
The lid wiper region of the eyelid is the portion of the marginal conjunctival epithelium that moves across the ocular surface or contact lens during blinking.
Participants were classified according to their lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00.
Grades range from 0 to 3, where higher grades indicate worsening lid wiper epitheliopathy.
|
One week post contact lens fitting
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lid Wiper Epitheliopathy
Time Frame: 2 hours post contact lens fitting
|
Lid Wiper Staining of the Upper Eyelid.
The lid wiper region of the eyelid is the portion of the marginal conjunctival epithelium that moves across the ocular surface or contact lens during blinking.
Participants were classified according to their lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00.
Grades range from 0 to 3, where higher grades indicate worsening lid wiper epitheliopathy.
|
2 hours post contact lens fitting
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eric R Ritchey, OD, PhD, University of Houston
- Principal Investigator: Rachel Redfern, OD, PhD, University of Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 26, 2017
Primary Completion (Actual)
April 13, 2018
Study Completion (Actual)
April 13, 2018
Study Registration Dates
First Submitted
June 30, 2017
First Submitted That Met QC Criteria
July 3, 2017
First Posted (Actual)
July 6, 2017
Study Record Updates
Last Update Posted (Actual)
August 31, 2021
Last Update Submitted That Met QC Criteria
August 27, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00000386
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lid Wiper Epitheliopathy
-
Meir Medical CenterUnknownMalposition of the Lower Lid
-
Johnson & Johnson Vision Care, Inc.CompletedLid-Parallel Conjunctival FoldsGermany
-
Wenzhou Medical UniversityNot yet recruitingSs-octa | Lid Margin Blood Flow Density | MGD
-
Kenneth BeerMedicis Pharmaceutical CorporationCompleted
-
Université de SherbrookeNot yet recruitingGlaucoma | Dry Eye | Corneal Disease | Corneal Epitheliopathy
-
Charite University, Berlin, GermanyMedical Park AGCompletedIncomplete Closure of Lid | Parotis Tumor | m. Orbicularis Oculi ParesisGermany
-
Bukwang PharmaceuticalContera Pharma ApSCompletedParkinson's Disease | Levodopa Induced Dyskinesia (LID)South Africa
-
Adamas Pharmaceuticals, Inc.CompletedParkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)France, Spain, United States, Germany, Austria
-
Adamas Pharmaceuticals, Inc.TerminatedParkinson's Disease | Levodopa Induced Dyskinesia (LID)France, Germany, Canada, United States, Spain
Clinical Trials on Acuvue Oasys
-
Johnson & Johnson Vision Care, Inc.Recruiting
-
Johnson & Johnson Vision Care, Inc.Completed
-
Nova Southeastern UniversityAmerican Academy of OptometryWithdrawnVisual Impairment | Low Vision | PhotophobiaUnited States
-
Ohio State UniversityNational Eye Institute (NEI); National Institutes of Health (NIH)Completed
-
State University of New York College of OptometryCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Johnson & JohnsonTerminatedRefractive Error | Astigmatism | MyopiaJapan